In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $825.00. The company’s shares closed yesterday at $760.73.
According to TipRanks, Bansal is a 4-star analyst with an average return of 8.3% and a 57.36% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Amgen.
In addition to Wells Fargo, Eli Lilly & Co also received a Buy from Truist Financial’s Robyn Karnauskas in a report issued on March 11. However, on March 8, Goldman Sachs maintained a Hold rating on Eli Lilly & Co (NYSE: LLY).
See today’s best-performing stocks on TipRanks >>
Based on Eli Lilly & Co’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $9.35 billion and a net profit of $2.19 billion. In comparison, last year the company earned a revenue of $7.3 billion and had a net profit of $1.94 billion
Based on the recent corporate insider activity of 166 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eli Lilly & Co (LLY) Company Description:
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
Read More on LLY:
- Amazon Ad Blunder: Merchants Charged for Promoting Goods that Consumers Couldn’t Buy
- Eli Lilly partnering with Amazon to deliver Zepbound, other drugs, Reuters says
- Wedbush upgrades AnaptysBio to Outperform into clinical catalysts
- Redwire, Lilly team on 2nd spaceflight mission for chronic disease research
- Eli Lilly CAO Zakrowski sells 750 common shares
